Luo Ying and Ping Lan Increase Stake in Gyre Therapeutics to 8.6% Following Cullgen Merger

On May 4, 2026, Ying Luo and spouse Ping Lan reported a significant increase in their holdings of Gyre Therapeutics, Inc. (GYRE) following the company's acquisition of Cullgen Inc. Under the terms of the Agreement and Plan of Merger, Gyre acquired Cullgen in an all-stock transaction valued at approximately $300 million. As part of the merger, Mr. Luo received options to purchase Company Common Stock in exchange for his Cullgen options. The reporting persons now beneficially own an aggregate of 10,211,387 shares, representing 8.6% of the class. This total includes 5,373,091 shares underlying options held by Mr. Luo, 2,575,541 shares held directly by Ms. Lan, and 2,262,755 shares underlying options held by Ms. Lan, all exercisable within 60 days. In connection with the transaction, the reporting persons entered into lock-up agreements restricting the transfer of these shares over staggered periods of 180 days, twelve months, and eighteen months. Additionally, a Registration Rights Agreement was established to facilitate the future resale of these securities.